Fig. 2From: Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumorsOverview of ctDNA tests. a Distribution of tumor types in 313 patients. b Fraction of patients with CCF values above 0.25%, 0.5%, 1%, and 5% grouped by cancer typesBack to article page